Notes | Project documents | Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146] | Guidance

Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2024.